New Horizons in the Treatment of
Psoriasis: Key Strategies to Target Optimal Patient Outcomes
A continuing medical education
activity provided by NAMCP and AAMCN
This activity is an archive of the live session from the 2021 Spring
Managed Care Forum.
If you participated in the live session, you are not eligible for
continuing education credits from this archive.
This activity is valid from June 1, 2021 – August 1, 2022
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
Novartis Pharmaceuticals Corporation and UCB
Psoriasis is a complex, chronic, immune-mediated inflammatory
disease that affects approximately 7 million of the population in
the United States. Psoriasis is a periodic flare-up of sharply
defined red patches, covered by a silvery, flaky surface. The
disease most commonly appears on the skin of the scalp, elbow,
knees, and lumbosacral areas of the body. Psoriasis is a complex
disease to manage, but the goal should be a patient-centered
treatment that reduces disease burden, improves on quality-of-life,
and addresses the risks of systemic complications and comorbid
conditions. The under diagnosis and treatment of psoriasis continues
to be a serious concern Once psoriasis is diagnosed through a
physical examination and a skin biopsy, treatment of the disease
will depend on which type of psoriasis, where it is, and the
severity of it. Novel treatments, such as biologics, work by
inhibiting different types of cytokines. The early biologics work by
inhibiting tumor necrosis (TNF)-alpha, a protein broadly involved in
inflammation. Newer biologics are more targeted to the inflammatory
pathways involved in psoriasis, which works by blocking two proteins
-- interleukin-17 and -23. These newer agents have been shown to be
effective in treating psoriasis and could also be safer given their
more specific action on the immune system. Recent research indicates
that both IL-23 and IL-17 play important roles in the development of
psoriatic plaques. Treatments that inhibit IL-23 and IL-17 have
shown promising data in safety and efficacy in clinical trials of
moderate-to-severe psoriasis. Recent breakthroughs, and a better
understanding of the pathogenesis of psoriasis, have been translated
into targeted and highly effective therapies providing fundamental
insights into the pathogenesis of chronic inflammatory diseases with
a dominant IL-23/Th17 axis.
Upon completion of this
activity, participants will be able to:
Describe how to use current
guidelines for evidence-based approaches to the treatment of
Explore strategies to assess
psoriasis severity and optimal ways to diagnosis disease
Analyze the mechanism of action,
safety, and efficacy of novel agents in targeting the underlying
pathophysiology of psoriasis
Assess key clinical challenges and
unmet needs in the management of psoriasis
Examine multidisciplinary and
patient-focused strategies to improve patient outcomes in
psoriasis and other comorbidities
Discuss the managed care
considerations of psoriasis by exploring where novel agents fit
into the current treatment paradigm
||Junko Takeshita, MD,
Assistant Professor of Dermatology
Assistant Professor of Epidemiology
University of Pennsylvania Perelman School of Medicine
Takeshita has received grants/research funding from
Pfizer. Her presentation has been reviewed for any bias.
MD has no financial relationships with ineligible
companies to disclose.
Jeremy Williams has no financial relationships with
ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial
relationships with ineligible companies to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by educational grants from
Novartis Pharmaceuticals Corporation and UCB
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue